CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $4.77 Consensus PT from Brokerages
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among […]
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among […]
